| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. |
| 10 Nov 2026 | 10-Q |
| 28 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
THIS AMENDMENT NO. 1 TO CREDIT AGREEMENT AND WAIVER (this “Amendment”) is made and entered into as of October 28, 2026, by and among SANUWAVE HEALTH, INC., a Nevada corporation (the “Company”), SANUWAVE, INC., a Delaware corporation, the... |
| 02 Oct 2026 |
Form 4: Tyler James, Director
Granted 11,286 Stock Option (right to buy) |
| 02 Oct 2026 |
Form 4: Frank Morgan C., Director
Granted 11,286 Stock Option (right to buy) |
| 02 Oct 2026 |
Form 4: Bazar Gregory Matthew, Director
Granted 11,286 Stock Option (right to buy) |
| 02 Oct 2026 |
Form 4: Blizard Jeffrey, Director
Granted 11,286 Stock Option (right to buy) |
| 02 Oct 2026 |
Form 4: Miller Ian D., Director
Granted 12,697 Stock Option (right to buy) |
| 25 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On September 23, 2026, Sanuwave Health, Inc., a Nevada corporation (the “Company”), received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, for th... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. |
| 06 Aug 2026 | 10-Q |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 30 Jul 2026 | SCHEDULE 13G/A |
| 13 Jul 2026 |
8-K: Results of Operations and Financial Condition
Sanuwave announces preliminary, unaudited revenues of $9.6 million to $9.8 million |
| 02 Jul 2026 |
Form 4: Blizard Jeffrey, Director
Granted 5,524 Stock Option (right to buy) |
| 02 Jul 2026 |
Form 4: Miller Ian D., Director
Granted 6,215 Stock Option (right to buy) |
| 02 Jul 2026 |
Form 4: Bazar Gregory Matthew, Director
Granted 5,524 Stock Option (right to buy) |
| 02 Jul 2026 |
Form 4: Tyler James, Director
Granted 5,524 Stock Option (right to buy) |
Loading...